229 related articles for article (PubMed ID: 35600392)
1. SOCS3 Acts as an Onco-immunological Biomarker With Value in Assessing the Tumor Microenvironment, Pathological Staging, Histological Subtypes, Therapeutic Effect, and Prognoses of Several Types of Cancer.
Dai L; Tao Y; Shi Z; Liang W; Hu W; Xing Z; Zhou S; Guo X; Fu X; Wang X
Front Oncol; 2022; 12():881801. PubMed ID: 35600392
[TBL] [Abstract][Full Text] [Related]
2. MXD3 as an onco-immunological biomarker encompassing the tumor microenvironment, disease staging, prognoses, and therapeutic responses in multiple cancer types.
Wu SY; Lin KC; Lawal B; Wu ATH; Wu CZ
Comput Struct Biotechnol J; 2021; 19():4970-4983. PubMed ID: 34584637
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of SOCS1/2/3/4 as potential prognostic biomarkers and correlate with immune infiltration in glioblastoma.
Dai L; Han Y; Yang Z; Zeng Y; Liang W; Shi Z; Tao Y; Liang X; Liu W; Zhou S; Xing Z; Hu W; Wang X
J Cell Mol Med; 2023 Aug; 27(15):2194-2214. PubMed ID: 37315184
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of suppressor of cytokine signaling proteins in human breast Cancer.
Sun M; Tang C; Liu J; Jiang W; Yu H; Dong F; Huang C; Rixiati Y
BMC Cancer; 2021 Jun; 21(1):696. PubMed ID: 34120621
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma.
Khan MGM; Ghosh A; Variya B; Santharam MA; Ihsan AU; Ramanathan S; Ilangumaran S
BMC Cancer; 2020 Aug; 20(1):774. PubMed ID: 32807134
[TBL] [Abstract][Full Text] [Related]
6. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
7. The N6-Methylandenosine-Related Gene
Jiang X; Shi Y; Chen X; Xu H; Huang X; Li L; Pu J
Front Mol Biosci; 2022; 9():773662. PubMed ID: 35309512
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the Roles of Suppressor of Cytokine Signaling-3 in Esophageal Carcinoma.
Yang X; Tian M; Lin Y; Li L; Sun X; Zhang Z; Kang M; Lin J
Hum Gene Ther; 2023 Jun; 34(11-12):495-517. PubMed ID: 36932739
[TBL] [Abstract][Full Text] [Related]
9. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
10. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme.
Zhou H; Miki R; Eeva M; Fike FM; Seligson D; Yang L; Yoshimura A; Teitell MA; Jamieson CA; Cacalano NA
Clin Cancer Res; 2007 Apr; 13(8):2344-53. PubMed ID: 17438093
[TBL] [Abstract][Full Text] [Related]
12. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
13. Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3.
Ventero MP; Fuentes-Baile M; Quereda C; Perez-Valeciano E; Alenda C; Garcia-Morales P; Esposito D; Dorado P; Manuel Barbera V; Saceda M
PLoS One; 2019; 14(2):e0212581. PubMed ID: 30811476
[TBL] [Abstract][Full Text] [Related]
14. Pan-cancer analysis of ASB3 and the potential clinical implications for immune microenvironment of glioblastoma multiforme.
Mu L; Han Z; Yu S; Wang A; Chen D; Kong S; Gu Y; Xu L; Liu A; Sun R; Long Y
Front Immunol; 2022; 13():842524. PubMed ID: 36618381
[TBL] [Abstract][Full Text] [Related]
15. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
16. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
17. PTPRN Serves as a Prognostic Biomarker and Correlated with Immune Infiltrates in Low Grade Glioma.
Li P; Chen F; Yao C; Zhu K; Zhang B; Zheng Z
Brain Sci; 2022 Jun; 12(6):. PubMed ID: 35741647
[TBL] [Abstract][Full Text] [Related]
18. Multi-omics analyses of CD276 in pan-cancer reveals its clinical prognostic value in glioblastoma and other major cancer types.
Dai L; Guo X; Xing Z; Tao Y; Liang W; Shi Z; Hu W; Zhou S; Wang X
BMC Cancer; 2023 Jan; 23(1):102. PubMed ID: 36717836
[TBL] [Abstract][Full Text] [Related]
19. A Comprehensive Analysis of the Glutathione Peroxidase 8 (GPX8) in Human Cancer.
Ren Z; He Y; Yang Q; Guo J; Huang H; Li B; Wang D; Yang Z; Tian X
Front Oncol; 2022; 12():812811. PubMed ID: 35402257
[TBL] [Abstract][Full Text] [Related]
20. Identification of the Prognostic Value Among Suppressor Of Cytokine Signaling Family Members in Kidney Renal Clear Cell Carcinoma.
Li C; Zhang W; Fang T; Li N; Wang Y; He L; He H
Front Mol Biosci; 2021; 8():585000. PubMed ID: 34926570
[No Abstract] [Full Text] [Related]
[Next] [New Search]
